The AKT1 Knockout AGS Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the AGS human gastric adenocarcinoma cell line. This product provides a loss-of-function model for the AKT1 gene, which encodes a critical serine/threonine kinase. The polyclonal format represents a heterogeneous pool of edited cells generated by Cas9-mediated gene disruption, offering a population-level assessment of AKT1 deficiency. This knockout model abolishes AKT1 protein function, enabling the study of its role in signal transduction and tumorigenesis without the phenotypic uniformity of a clonal line.
AGS is a widely characterized human gastric epithelial cell line established from a gastric adenocarcinoma. These cells retain hallmark features of gastric cancer, including active PI3K/AKT signaling that drives their proliferation and survival. The adherent epithelial morphology and well-documented genomic background make AGS a relevant and tractable host for dissecting AKT1-dependent mechanisms in a disease-relevant context. It is commonly employed in cancer biology research and drug development studies focused on gastric cancer pathogenesis, metastasis, and therapeutic resistance.
AKT1 is a serine/threonine kinase that functions as a central node in the PI3K/AKT signaling pathway. Upon stimulation, receptor tyrosine kinases such as EGFR and IGF1R activate PI3K to produce PIP3, which recruits AKT1 to the plasma membrane via its PH domain. At the membrane, AKT1 is phosphorylated and activated by PDK1 at Thr308 and mTORC2 at Ser473. Active AKT1 phosphorylates a diverse set of downstream substrates, including TSC2 and PRAS40 (which regulate mTORC1), GSK3??, FOXO transcription factors, BAD, and Caspase-9, thereby promoting cell survival, proliferation, growth, metabolism, and angiogenesis. The phosphatase PTEN opposes this pathway, and key interacting factors include PDPK1 (PDK1), RICTOR, SIN1, HSP90, and Cdc37. Knockout of AKT1 eliminates these phosphorylation events, disrupting multiple effector pathways such as mTOR, FoxO, and cell cycle progression.
In AGS gastric adenocarcinoma cells, the PI3K/AKT pathway is frequently hyperactivated, conferring proliferative advantages and resistance to apoptosis. Deletion of AKT1 in this background abrogates the primary effector of this cascade, leading to markedly reduced cell growth, impaired colony formation, and increased sensitivity to apoptotic stimuli. The polyclonal knockout model enables population-level studies of AKT1 loss, facilitating investigations into gastric cancer cell migration, invasion, and metabolic reprogramming. Its intrinsic heterogeneity partially reflects the diversity found in tumors, providing a translationally relevant tool for studying drug resistance and pathway interplay.
The AKT1 Knockout AGS Polyclonal Cells are suited for a broad range of applications, including Western blot analysis of phospho-AKT (Ser473, Thr308) and downstream targets, cell viability assays using MTT or CellTiter-Glo, apoptosis detection via Annexin V staining, colony formation assays, and transwell migration/invasion studies. They are also valuable in phospho-kinase arrays and xenograft tumor growth models to assess tumorigenicity. Additionally, the knockout line serves as a control for rescue experiments and enables detailed investigation of drug resistance mechanisms and metabolic shifts in gastric cancer. For further information and ordering details, please contact Ascent Research.
